The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
The 2025 Appropriate Use Criteria for implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT), and pacing have been released. This year’s guideline is broader than ...
SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating ...
Electrophysiologists at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin recently became the first in the U.S. to implant an FDA-approved leadless system for cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results